{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:33:29Z","timestamp":1787970809422,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004913","name":"Universit\u00e0 degli Studi di Palermo","doi-asserted-by":"publisher","award":["FFR-2023"],"award-info":[{"award-number":["FFR-2023"]}],"id":[{"id":"10.13039\/501100004913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Cystic Fibrosis Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.gene.2025.149384","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:23:05Z","timestamp":1741191785000},"page":"149384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["RNA editing applied to cystic fibrosis: RESTORE can target G542X CFTR mRNA and revert the nonsense mutation"],"prefix":"10.1016","volume":"951","author":[{"given":"Simona","family":"Titoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7186-4485","authenticated-orcid":false,"given":"Viviana","family":"Barra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3955-9933","authenticated-orcid":false,"given":"Serena","family":"Gargano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Di Leonardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4463-8156","authenticated-orcid":false,"given":"Raffaella","family":"Melfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2025.149384_b0005","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.omtn.2019.12.042","article-title":"Novel engineered programmable systems for ADAR-mediated RNA editing","volume":"19","author":"Aquino-Jarquin","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.gene.2025.149384_b0010","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/genes13071125","article-title":"Specific irreversible cell-cycle arrest and depletion of cancer cells obtained by combining curcumin and the flavonoids quercetin and fisetin","volume":"13","author":"Barra","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.gene.2025.149384_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1092913","article-title":"Programmable RNA editing with endogenous ADAR enzymes - a feasible option for the treatment of inherited retinal disease?","volume":"16","author":"Bellingrath","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.gene.2025.149384_b0020","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.ymthe.2023.01.005","article-title":"RNA editing: Expanding the potential of RNA therapeutics","volume":"31","author":"Booth","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.gene.2025.149384_b0025","doi-asserted-by":"crossref","first-page":"9609","DOI":"10.3390\/ijms24119609","article-title":"Investigating the Inhibition of FTSJ1, a Tryptophan tRNA-Specific 2\u2032-O-Methyltransferase by NV TRIDs, as a Mechanism of Readthrough in Nonsense Mutated CFTR","volume":"24","author":"Carollo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.gene.2025.149384_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310940","article-title":"Site-Specific RNA Editing of Stop Mutations in the CFTR mRNA of Human Bronchial Cultured Cells","volume":"24","author":"Chiavetta","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.gene.2025.149384_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113886","article-title":"Nonsense codons suppression. An acute toxicity study of three optimized TRIDs in murine model, safety and tolerability evaluation","volume":"156","author":"Corrao","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.gene.2025.149384_b0040","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.gene.2025.149384_b0045","unstructured":"Cystic Fibrosis Mutation Database URL http:\/\/genet.sickkids.on.ca\/ (accessed 2.9.24)."},{"key":"10.1016\/j.gene.2025.149384_b0050","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.tig.2021.04.013","article-title":"The New RNA-Editing Era \u2013 Ethical Considerations","volume":"37","author":"Gold","year":"2021","journal-title":"Trends Genet."},{"key":"10.1016\/j.gene.2025.149384_b0055","doi-asserted-by":"crossref","first-page":"9580","DOI":"10.1093\/nar\/gkac713","article-title":"Programmable RNA base editing with a single gRNA-free enzyme","volume":"50","author":"Han","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.gene.2025.149384_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102247","article-title":"CFTR RNA- and DNA-based therapies","volume":"65","author":"Harrison","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.gene.2025.149384_b0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41592-019-0323-0","article-title":"In vivo RNA editing of point mutations via RNA-guided adenosine deaminases","volume":"16","author":"Katrekar","year":"2019","journal-title":"Nat. Methods"},{"key":"10.1016\/j.gene.2025.149384_b0070","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1021\/mp400230s","article-title":"Toward a Rationale for the PTC124 (Ataluren) Promoted Readthrough of Premature Stop Codons: A Computational Approach and GFP-Reporter Cell-Based Assay","volume":"11","author":"Lentini","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.gene.2025.149384_b0075","article-title":"Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics","volume":"2","author":"Mansoor","year":"2008","journal-title":"Gene Regul. Syst. Biol."},{"key":"10.1016\/j.gene.2025.149384_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108350","article-title":"Evaluation of engineered CRISPR-Cas-mediated systems for site-specific RNA editing","volume":"33","author":"Marina","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.gene.2025.149384_b0085","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.3390\/ijms21134781","article-title":"Investigating REPAIRv2 as a Tool to Edit CFTR mRNA with Premature Stop Codons","volume":"21","author":"Melfi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.gene.2025.149384_b0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41587-019-0013-6","article-title":"Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides","volume":"37","author":"Merkle","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.gene.2025.149384_b0095","doi-asserted-by":"crossref","first-page":"18285","DOI":"10.1073\/pnas.1306243110","article-title":"Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing","volume":"110","author":"Montiel-Gonzalez","year":"2013","journal-title":"Proc. Natl. Acad. Sci. u. s. a."},{"key":"10.1016\/j.gene.2025.149384_b0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrm.2015.4","article-title":"A-to-I editing of coding and non-coding RNAs by ADARs","volume":"17","author":"Nishikura","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.gene.2025.149384_b0105","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1128\/MCB.15.10.5376","article-title":"Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase","volume":"15","author":"Patterson","year":"1995","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.gene.2025.149384_b0110","doi-asserted-by":"crossref","first-page":"15084","DOI":"10.3390\/ijms242015084","article-title":"Readthrough Approach Using NV Translational Readthrough-Inducing Drugs (TRIDs): A Study of the Possible Off-Target Effects on Natural Termination Codons (NTCs) on TP53 and Housekeeping Gene Expression","volume":"24","author":"Perriera","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.gene.2025.149384_b0115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcf.2021.09.020","article-title":"Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids","volume":"21","author":"de Poel","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.gene.2025.149384_b0120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fphar.2019.00121","article-title":"Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine","volume":"10","author":"Pranke","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.gene.2025.149384_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1389586","article-title":"Readthrough-induced misincorporated amino acid ratios guide mutant-specific therapeutic approaches for two CFTR nonsense mutations","volume":"15","author":"Premchandar","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.gene.2025.149384_b0130","doi-asserted-by":"crossref","first-page":"7350","DOI":"10.1073\/pnas.78.12.7350","article-title":"A DNA fragment with an alpha-phosphorothioate nucleotide at one end is asymmetrically blocked from digestion by exonuclease III and can be replicated in vivo","volume":"78","author":"Putney","year":"1981","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.gene.2025.149384_b0135","doi-asserted-by":"crossref","first-page":"e1594","DOI":"10.1002\/wrna.1594","article-title":"The powerful world of antisense oligonucleotides: from bench to bedside","volume":"11","author":"Quemener","year":"2020","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"10.1016\/j.gene.2025.149384_b0140","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02443-2019","article-title":"Re-imagining cystic fibrosis care: next generation thinking","volume":"55","author":"Rang","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.gene.2025.149384_b0145","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0042-1758851","article-title":"CFTR Modulators: current status and evolving knowledge","volume":"44","author":"Regard","year":"2023","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.gene.2025.149384_b0150","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1038\/s41467-021-24575-x","article-title":"A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion","volume":"12","author":"Sharma","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.gene.2025.149384_b0155","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2018.12.001","article-title":"Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells","volume":"18","author":"Valley","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.gene.2025.149384_b0160","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jcp.24976","article-title":"p14ARF prevents proliferation of aneuploid cells by inducing p53-dependent apoptosis","volume":"231","author":"Veneziano","year":"2016","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.gene.2025.149384_b0165","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1073\/pnas.97.10.5633","article-title":"Potent and nontoxic antisense oligonucleotides containing locked nucleic acids","volume":"97","author":"Wahlestedt","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.gene.2025.149384_b0170","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3390\/cells12121555","article-title":"Genome editing for cystic fibrosis","volume":"12","author":"Wang","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.gene.2025.149384_b0175","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1261\/rna.5160403","article-title":"Elevated activity of the large form of ADAR1 in vivo: very efficient RNA editing occurs in the cytoplasm","volume":"9","author":"Wong","year":"2003","journal-title":"RNA"},{"key":"10.1016\/j.gene.2025.149384_b0180","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41592-021-01124-4","article-title":"Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated microbes","volume":"18","author":"Xu","year":"2021","journal-title":"Nat. Methods"},{"key":"10.1016\/j.gene.2025.149384_b0185","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/hmg\/ddx196","article-title":"Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences","volume":"26","author":"Xue","year":"2017","journal-title":"Hum. Mol. Genet."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111925001726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111925001726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T20:14:56Z","timestamp":1742674496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111925001726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":37,"alternative-id":["S0378111925001726"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2025.149384","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA editing applied to cystic fibrosis: RESTORE can target G542X CFTR mRNA and revert the nonsense mutation","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2025.149384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"149384"}}